

Note to readers with disabilities: *EHP* strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in *EHP* articles may not conform to [508 standards](#) due to the complexity of the information being presented. If you need assistance accessing journal content, please contact ehp508@niehs.nih.gov. Our staff will work with you to assess and meet your accessibility needs within 3 working days.

Supplemental Material

Maternal Smoking during Pregnancy and Early Childhood and Development of Asthma and Rhinoconjunctivitis – a MeDALL Project

Jesse D. Thacher, Ulrike Gehring, Olena Gruzieva, Marie Standl, Göran Pershagen, Carl-Peter Bauer, Dietrich Berdel, Theresa Keller, Sibylle Koletzko, Gerard H. Koppelman, Inger Kull, Susanne Lau, Irina Lehmann, Dieter Maier, Tamara Schikowski, Ulrich Wahn, Alet H. Wijga, Joachim Heinrich, Jean Bousquet, Josep M. Anto, Andrea von Berg, Erik Melén, Henriette A. Smit, Thomas Keil, and Anna Bergström

Table of Contents

Table S1. Definitions of smoking variables in the participating birth cohorts.

Table S2. Definitions of asthma and rhinoconjunctivitis variables in the participating birth cohorts.

Table S3. Overview of follow-ups of participating cohorts and outcome assessment intervals.

Table S4. Participant characteristics of five European birth cohorts at baseline.

Table S5. Association between SHS exposure during pregnancy and during infancy in relation to prevalent asthma and rhinoconjunctivitis up to 14 to 16 years from one-stage IPD-MA.

Table S6. The development of early-onset and persistent phenotypes of asthma and rhinoconjunctivitis in relation to intensity of SHS during infancy.

Table S7. Asthma and rhinoconjunctivitis development in relation to smoking during pregnancy stratified by parental allergy.

Table S8. Asthma and rhinoconjunctivitis development in relation to smoking during infancy stratified by parental allergy.

Table S9. Asthma and rhinoconjunctivitis development in relation to smoking during pregnancy stratified by sex.

Table S10. Asthma and rhinoconjunctivitis risk in relation to smoking during infancy stratified by sex.

Table S11. Association between SHS exposure during pregnancy and during infancy in relation to prevalent asthma and rhinoconjunctivitis up to 14 to 16 years from one-stage IPD-MA excluding preterm infants.

Figure S1. Prevalence of parental tobacco smoking in five European birth cohorts.

Figure S2. Prevalence of clinical phenotypes in five European birth cohorts.

Figure S3. Secondhand smoking during infancy and the development of early-transient, persistent, and adolescent-onset disease phenotypes.

Figure S4. Association between maternal smoking during pregnancy and asthma only, rhinoconjunctivitis only, or concurrent asthma and rhinoconjunctivitis up to 14 to 16 years of age in five European birth cohorts. Cohort specific odds ratios (OR) and 95% confidence intervals (CI) were obtained by GEE models adjusted for sex, parental education level, parental allergy, older siblings, breastfeeding, study center, intervention arm, and early day-care attendance. Combined OR and 95% CI were derived from cohort-specific OR and 95% CI using a random effects model.

Figure S5. Association between parental smoking during infancy and asthma only, rhinoconjunctivitis only, or concurrent asthma and rhinoconjunctivitis up to 14 to 16 years of age in five European birth cohorts. Cohort specific odds ratios (OR) and 95% confidence intervals (CI) were obtained by GEE models adjusted for sex, parental education level, parental allergy, older siblings, breastfeeding, study center, intervention arm, and early day-care attendance. Combined OR and 95% CI were derived from cohort-specific OR and 95% CI using a random effects model.

Figure S6. Associations between maternal smoking during pregnancy only, SHS during infancy only, and both in relation to asthma and rhinoconjunctivitis.

Figure S7. Associations between any tobacco smoke exposure during pregnancy or SHS during infancy and prevalence of asthma and rhinoconjunctivitis up to 14 to 16 years of age in five European birth cohorts. Cohort specific odds ratios (OR) and 95% confidence intervals (CI) were obtained by generalized estimating equation models adjusted for sex, parental education level, parental allergy, older siblings, breastfeeding, study center, intervention arm, and early day-care attendance. Combined OR and 95% CI were derived from cohort-specific OR and 95% CI using a random effects model. Participants unexposed to tobacco smoke during pregnancy and infancy comprised the reference category.